Cited by 217Renal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesAcute Kidney Injury Research

The DOI matches its Crossref record, with a small difference in title or year; 167 of the 168 references it cites were found in a registry or an index.

Management of Glomerular Proteinuria: A Commentary

Wilmer, William A., Rovin, Brad H., Hebert, Christopher J., Rao, Sunil V., Kumor, Karen, Hebert, Lee A.·2003·Journal of the American Society of Nephrology

DOI 10.1097/01.asn.0000100145.27188.33

Open this paper in CoChat — free account

Abstract

It is widely accepted that proteinuria reduction is an appropriate therapeutic goal in chronic proteinuric kidney disease. Based on large randomized controlled clinical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy have emerged as the most important antiproteinuric and renal protective interventions. However, there are numerous other interventions that have been shown to be antiproteinuric and, therefore, likely to be renoprotective. Unfortunately testing each of these antiproteinuric therapies in RCT is not feasible. The nephrologist has two choices: restrict antiproteinuric therapies to those shown to be effective in RCT or expand the use of antiproteinuric therapies to include those that, although unproven, are plausibly effective and prudent to use. The goal of this work is to provide the documentation needed for the nephrologist to choose between these strategies. This work describes 25 separate interventions that are either antiproteinuric or may block injurious mechanisms of proteinuria. Each intervention is assigned a level of recommendation (Level 1 is the highest; Level 3 is the lowest) according to the strength of the evidence supporting its antiproteinuric and renoprotective efficacy. Pathophysiologic mechanisms possibly involved are also discussed. The number of interventions at each level of recommendation are: Level 1, n = 7; Level 2, n = 9; Level 3, n = 9. Our experience indicates that we can achieve in most patients the maj…

Integrity signals

Registry

Crossref · 10.1097/01.asn.0000100145.27188.33

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 947
Retracted
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604

Show all 168 references

Sorted by citations

Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S. M., Prosek, J. M., Nádasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,392
Self-citation
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
Ogihara, T., Kikuchi, K. M., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., Iwao, H., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,384
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 863
Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 716
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Cell Biology and Pathology of Podocytes
Greka, A., & Mundel, P. H. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153238 · Cited by 530
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease
Remuzzi, G., Perico, N., Macia, M. L., & Ruggenenti, P. L. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09911.x · Cited by 513
Progression of nephropathy in type 2 diabetic patients
Rossing, K., Christensen, P. K., Hovind, P. H., Tarnow, L., Rossing, P. R., & Parving, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00925.x · Cited by 339
Primary glomerulonephritides
Floege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
Proteinuria: an enzymatic disease of the podocyte?
Mundel, P. H., & Reiser, J. (2009) · Kidney International · doi:10.1038/ki.2009.424 · Cited by 271
Urine Chemokines as Biomarkers of Human Systemic Lupus Erythematosus Activity
Rovin, B. H., Song, H., Birmingham, D. J., Hebert, L. A., Yu, C. Y., & Nagaraja, H. N. (2004) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080658 · Cited by 266
Self-citation
Proteinuria: detection and role in native renal disease progression
Górriz, J. L., & Martínez‐Castelao, A. (2011) · Transplantation Reviews · doi:10.1016/j.trre.2011.10.002 · Cited by 266
Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
Guidelines, S. (2006) · Hypertension Research · Cited by 216
Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
Japanese Society of Hypertension (2006) · Hypertension Research · doi:10.1291/hypres.29.s1 · Cited by 217
Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia
Hsu, T.-W., Liu, J., Hung, S., Kuo, K., Chang, Y., Chen, Y., Hsu, C.-C., & Tarng, D. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12700 · Cited by 219
Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker
Chrysostomou, A., Pedagogos, E., MacGregor, L., & Becker, G. J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01040905 · Cited by 209
Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus
Rovin, B. H., Song, H., Hebert, L. A., Nádasdy, T., Nadasdy, G. M., Birmingham, D. J., Yu, C. Y., & Nagaraja, H. N. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00601.x · Cited by 154
Self-citation
Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial
Cardiel, M. H., Tumlin, J. A., Furie, R. A., Wallace, D. J., Joh, T., & Linnik, M. D. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23673 · Cited by 147
Surrogate End Points for Clinical Trials of Kidney Disease Progression
Stevens, L. A., Greene, T., & Levey, A. S. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00600206 · Cited by 132
Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio
Methven, S., MacGregor, M. S., Traynor, J. P., O’Reilly, D. S. J., & Deighan, C. J. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq140 · Cited by 126
Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice
Gaspari, F., Perico, N., & Remuzzi, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.014 · Cited by 125
Hyperkalemia in Heart Failure
Sarwar, C. M. S., Papadimitriou, L., Pitt, B., Piña, I. L., Zannad, F. M., Anker, S. D., Gheorghiade, M., & Butler, J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.060 · Cited by 117
Therapeutic strategies to slow chronic kidney disease progression
Wühl, E., & Schaefer, F. S. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0789-y · Cited by 109
Diabetic Nephropathy: The Proteinuria Hypothesis
Williams, M. E. (2005) · American Journal of Nephrology · doi:10.1159/000084286 · Cited by 108
Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature
Pisani, A., Visciano, B., Diez‐Roux, G., Sabbatini, M., Porto, C., Parenti, G., & Imbriaco, M. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.08.003 · Cited by 100
Current Therapy for IgA Nephropathy
Floege, J., & Eitner, F. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011030221 · Cited by 92
Treatment of IgA nephropathy and Henoch–Schönlein nephritis
Floege, J., & Feehally, J. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.59 · Cited by 89
Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis.
Christopher‐Stine, L., Petri, M., Astor, B. C., & Fine, D. M. (2004) · PubMed · Cited by 87
Proteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease
Palmer, B. F. (2007) · American Journal of Nephrology · doi:10.1159/000101958 · Cited by 82
Mycophenolate therapy of SLE membranous nephropathy
Spetie, D. N., Tang, Y., Rovin, B. H., Nádasdy, T., Nadasdy, G. M., Pesavento, T. E., & Hebert, L. A. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.66030.x · Cited by 82
Self-citation
Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression
Catapano, F., Chiodini, P., Nicola, L. D., Minutolo, R., Zamboli, P., Gallo, C., & Conte, G. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.03.008 · Cited by 82
ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials
Cheng, J., Zhang, W., Zhang, X. H., He, Q., Tao, X. J., & Jh, C. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02038.x · Cited by 75
Peripheral blood dendritic cells and GM-CSF as an adjuvantfor hepatitis B vaccination in hemodialysis patients
Verkade, M. A., van de Wetering, J., Klepper, M., Vaessen, L. M. B., Weimar, W. W., & Betjes, M. G. H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00781.x · Cited by 75
The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy
Feriozzi, S., Torrás, J., Cybulla, M., Nicholls, K., Sunder–Plassmann, G., & West, M. L. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03130411 · Cited by 75
Supportive Versus Immunosuppressive Therapy of Progressive IgA Nephropathy (STOP) IgAN trial: rationale and study protocol
Eitner, F., Ackermann, D., Hilgers, R.-D., & Floege, J. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.3.284 · Cited by 74
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares
Birmingham, D. J., Rovin, B. H., Shidham, G. B., Nagaraja, H. N., Zou, X., Bissell, M. G., Yu, C. Y., & Hebert, L. A. (2007) · Kidney International · doi:10.1038/sj.ki.5002421 · Cited by 71
Self-citation
Chronic renal allograft injury: early detection, accurate diagnosis and management
Pascual, J., Pérez‐Sáez, M. J., Mir, M., & Crespo, M. (2012) · Transplantation Reviews · doi:10.1016/j.trre.2012.07.002 · Cited by 73
Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index
Petri, M., Kasitanon, N., Lee, S., Link, K., Magder, L. S., Bae, S., Hanly, J. G., Isenberg, D. A., Nived, O., Sturfelt, G. K., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23456 · Cited by 70
Self-citation
Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy
Rovin, B. H., Tang, Y., Sun, J., Nagaraja, H. N., Hackshaw, K. V., Gray, L., Rice, R. R., Birmingham, D. J., Yu, C. Y., Spetie, D. N., et al. (2005) · Kidney International · doi:10.1016/s0085-2538(15)50895-8 · Cited by 64
Self-citation
Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions
Pascual, J., Boletis, I. N., & Campistol, J. M. (2006) · Transplantation Reviews · doi:10.1016/j.trre.2005.10.005 · Cited by 62
Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse
Tanabe, K., Lanaspa, M. A., Kitagawa, W., Rivard, C. J., Miyazaki, M., Klawitter, J., Schreiner, G. F., Saleem, M. A., Mathieson, P. W., Makino, H., et al. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00596.2011 · Cited by 55
Chapter 12: Lupus nephritis
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.25 · Cited by 54
Oral Cyclophosphamide for Lupus Glomerulonephritis
McKinley, A. M., Park, E., Spetie, D. N., Hackshaw, K. V., Nagaraja, S., Hebert, L. A., & Rovin, B. H. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02670409 · Cited by 54
Self-citation
Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice
Shidham, G. B., & Hebert, L. A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.013 · Cited by 52
Self-citation
FVB mouse genotype confers susceptibility to OVE26 diabetic albuminuria
Xu, J., Huang, Y., Li, F., Zheng, S., & Epstein, P. N. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00018.2010 · Cited by 51
Managing kidney disease with blood-pressure control
Wühl, E., & Schaefer, F. S. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.73 · Cited by 47
Plasmapheresis for the Prophylaxis and Treatment of Recurrent Focal Segmental Glomerulosclerosis Following Renal Transplant
Valdivia, P., Roncero, F. G., Gentil, M. A., Jiménez, F., Algarra, G., Pereira, P., Rivera, M., Suñer, M., Cabello, V., Toro, J., et al. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.02.061 · Cited by 47
Membranous Lupus Nephritis: A Clinical Review
Almaani, S. J., & Parikh, S. V. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.009 · Cited by 47
Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?
Meyrier, A. Y. (2009) · Kidney International · doi:10.1038/ki.2009.204 · Cited by 45
Screening for chronic kidney disease in emerging countries: feasibility and hurdles
Perico, N., Bravo, R. F., León, F. R. D., & Remuzzi, G. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp039 · Cited by 45
Boldine Improves Kidney Damage in the Goldblatt 2K1C Model Avoiding the Increase in TGF-β
Gómez, G. I., & Velarde, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071864 · Cited by 41
Random Spot Urine Protein/Creatinine Ratio Is Unreliable for Estimating 24-Hour Proteinuria in Individual Systemic Lupus Erythematosus Nephritis Patients
Hebert, L. A., Birmingham, D. J., Shidham, G. B., Rovin, B. H., Nagaraja, H. N., & Yu, C. Y. (2009) · Nephron Clinical Practice · doi:10.1159/000232599 · Cited by 41
Self-citation
Assessment of proteinuria level in nephrology patients using a machine learning approach
Scala, A., Loperto, I., Carrano, R., Federico, S., Triassi, M., & Improta, G. (2021) · International Conference on Medical and Health Informatics (ICMHI) · doi:10.1145/3472813.3472816 · Cited by 40
Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis
Cheng, J.-W., Zhang, X., Tian, J., Li, Q., & Chen, J.-M. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02970.x · Cited by 40
Detection and measurement of urinary protein
Polkinghorne, K. R. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000247502.49044.10 · Cited by 39
Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): Rationale and Study Design
Imai, E., Ito, S., Haneda, M., Chan, J. C. N., & Makino, H. (2006) · Hypertension Research · doi:10.1291/hypres.29.703 · Cited by 38
Proteinuria and Microalbuminuria in Adults: Significance, Evaluation, and Treatment
Venkat, K. K. (2004) · Southern Medical Journal · doi:10.1097/01.smj.0000140833.51533.46 · Cited by 37
Relationship between Albuminuria and Total Proteinuria in Systemic Lupus Erythematosus Nephritis
Birmingham, D. J., Rovin, B. H., Shidham, G. B., Bissell, M. G., Nagaraja, H. N., & Hebert, L. A. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04761107 · Cited by 36
Self-citation
Primary Care Approach to Proteinuria
Naderi, A. S. A., & Reilly, R. F. (2008) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2008.06.070080 · Cited by 35
Simvastatin protection against acute immune-mediated glomerulonephritis in mice
CHRISTENSEN, M. B., Su, A. W., Snyder, R. W., Greco, A. J., Lipschutz, J. H., & Madaio, M. P. (2006) · Kidney International · doi:10.1038/sj.ki.5000086 · Cited by 34
Norcantharidin Ameliorates Proteinuria, Associated Tubulointerstitial Inflammation and Fibrosis in Protein Overload Nephropathy
Liu, F. Y., Li, Y., Peng, Y., Ye, K., Li, ., Liu, Y., Duan, S., Ling, G., Xu, X., & Zhou, L. (2008) · American Journal of Nephrology · doi:10.1159/000112850 · Cited by 34
A Review of the Potential Benefits of Pentoxifylline in Diabetic and Non-Diabetic Proteinuria
Badri, S., Dashti‐Khavidaki, S., Lessan‐Pezeshki, M., & Abdollahi, M. R. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3bp4g · Cited by 32
An update on the treatment options for focal segmental glomerulosclerosis
Meyrier, A. Y. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902754029 · Cited by 31
Slowing the Progression of Adult Chronic Kidney Disease
Taal, M. W. (2004) · Drugs · doi:10.2165/00003495-200464200-00002 · Cited by 31
Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease
Prabakaran, T., Birn, H., Bibby, B. M., Regeniter, A., Sørensen, S. S., Feldt-Rasmussen, U., Nielsen, R., & Christensen, E. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft452 · Cited by 30
Medaka fish, Oryzias latipes, as a model for human obesity-related glomerulopathy
Ichimura, K., Kawashima, Y., Nakamura, T., Powell, R., Hidoh, Y., Terai, S., Sakaida, I., Kodera, Y., Tsuji, T., Ma, J., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.053 · Cited by 28
Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood
Mastrangelo, A., Serafinelli, J., Giani, M., & Montini, G. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00205 · Cited by 27
Recent changes in the landscape of combination RAS blockade
Epstein, B. J., Smith, S. M., & Choksi, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.127 · Cited by 27
Navigating Between the Scylla and Charybdis of Prescribing Dietary Protein for Chronic Kidney Diseases
Franch, H. A., & Mitch, W. E. (2009) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-080508-141051 · Cited by 26
Renal protection in IgA nephropathy requires strict blood pressure control
Nagy, J., Kovács, T., & Wittmann, I. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh920 · Cited by 26
Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Trimarchi, H. (2015) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1872214809666150302104542 · Cited by 25
Effect of Add-on Pentoxifylline on Proteinuria in Membranous Glomerulonephritis: A 6-month Placebo-controlled Trial
Badri, S., Dashti‐Khavidaki, S., Ahmadi, F., Mahdavi‐Mazdeh, M., Abbasi, M.-R., & Khalili, H. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0057-1 · Cited by 25
Focal and Segmental Glomerulosclerosis: Multiple Pathways Are Involved
Meyrier, A. Y. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.06.003 · Cited by 24
Immune Modulating Therapy for IgA Nephropathy: Rationale and Evidence
Floege, J., & Eitner, F. (2008) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.10.005 · Cited by 24
My Doctor Said I Should Drink a Lot! Recommendations for Fluid Intake in Patients with Chronic Kidney Disease
Wenzel, U. O., Hebert, L. A., Stahl, R. A. K., & Krenz, I. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01140905 · Cited by 24
Self-citation
Optimizing ACE-Inhibitor Therapy for Chronic Kidney Disease
Hebert, L. A. (2006) · New England Journal of Medicine · doi:10.1056/nejme058295 · Cited by 24
Self-citation
Treatment of Primary Chronic Glomerulonephritis with Rehmannia Glutinosa Acteosides in Combination with the Angiotensin Receptor Blocker Irbesartan: A Randomized Controlled Trial
Qiu, H., Fu, P., Fan, W., Zuo, C., Feng, P., Shi, P., Cao, L., Liu, F., Zhou, L., Chen, F., et al. (2013) · Phytotherapy Research · doi:10.1002/ptr.4973 · Cited by 23
Nutritional treatment in chronic kidney disease: the concept of nephroprotection
Riccio, E., Nuzzi, A. D., & Pisani, A. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-014-1041-7 · Cited by 23
Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria
Borba, E. F., Guedes, L. K. N., Christmann, R., Figueiredo, C. P., Gonçalves, C. R., & Bonfá, E. (2006) · Rheumatology International · doi:10.1007/s00296-006-0142-3 · Cited by 23
General acteoside of rehmanniae leaves in the treatment of primary chronic glomerulonephritis: A randomized controlled trial
Qiu, H., Fan, W., Fu, P., Zuo, C., Feng, P., Liu, F., Zhou, L., Chen, F., Zhong, H., Liang, Y., et al. (2013) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v10i4.18 · Cited by 22
Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
Makhlough, A., Kashi, Z., Akha, O., Zaboli, E., & Charati, J. Y. (2014) · Nephro-Urology Monthly · doi:10.5812/numonthly.12148 · Cited by 22
Anaplastic Lymphoma Kinase activating mechanisms and signaling pathways
Inghirami, G. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/441 · Cited by 22
Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis
Li, Y., Ge, Y. L., Liu, F. Y., Peng, Y., Sun, L., Li, J., Chen, Q., Sun, Y., & Ye, K. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1091-z · Cited by 21
Introduction to Glomerular Disease
Floege, J., & Feehally, J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00015-0 · Cited by 21
Factors influencing reported rates of treated end-stage renal disease
McDonald, S. P., McCredie, M. R. E., Williams, S., & Stewart, J. H. (2005) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2004.10.011 · Cited by 21
Machine-learning enhancement of urine dipstick tests for chronic kidney disease detection
Jang, E. C., Park, Y. M., Han, H. W., Lee, C. S., Kang, E. S., Lee, Y. H., & Nam, S. M. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad051 · Cited by 20
Spot urine protein/creatinine ratio as a reliable estimate of 24-hour proteinuria in patients with immunoglobulin A nephropathy, but not membranous nephropathy
Kobayashi, S., Amano, H., Terawaki, H., Ogura, M., Kawaguchi, Y., & Yokoo, T. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1486-8 · Cited by 20
Retarding Progression of Kidney Disease
Brown, C., Haddad, N. F., & Hebert, L. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00076-9 · Cited by 20
Self-citation
To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective
Adarkwah, C. C., Gandjour, A., Akkerman, M. K., & Evers, S. (2013) · Kidney & Blood Pressure Research · doi:10.1159/000350142 · Cited by 19
The Kidney: Medical Nutrition Therapy—Yesterday and Today
Kalista-Richards, M. (2011) · Nutrition in Clinical Practice · doi:10.1177/0884533611399923 · Cited by 19
Urine liver fatty acid binding protein and chronic kidney disease progression
Khatir, D. S., Bendtsen, M. D., Birn, H., Nørregaard, R., Ivarsen, P., Jespersen, B., & Buus, N. H. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1355561 · Cited by 19
ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?
Lewis, E. J., & Lewis, J. B. (2004) · PubMed · Cited by 18
Minor Glomerular Abnormalities are Associated with Deterioration of Long-Term Kidney Function and Mitochondrial Injury
Yu, B. C., Cho, N., Park, S., Kim, H., Gil, H., Lee, E. Y., Kwon, S. H., Jeon, J. S., Noh, H., Han, D. C., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010033 · Cited by 18
Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad cardiovascular.: Versión Abreviada
Marin, R., Goicoechea, M., Gorostidi, M., Cases, A., Dı́ez, J., Escolar, G., Fernández-Vega, F., Palomar, R., Rodrigo, E., Martínez, I., et al. (2006) · Nefrología · Cited by 18
Épidémiologie des maladies rénales chroniques
Frimat, L., Ayav, C., Briançon, S., & Kessler, M. (2005) · Encyclopédie médico-chirurgicale. Néphrologie · doi:10.1016/j.emcnep.2005.09.003 · Cited by 18
Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis
Shidham, G. B., Ayoub, I. M., Birmingham, D. J., Hebert, P. L., Rovin, B. H., Diamond, B., Wofsy, D., & Hebert, L. A. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.04.010 · Cited by 17
Self-citation
Chronic allograft nephropathy – a clinical syndrome: early detection and the potential role of proliferation signal inhibitors
Campistol, J. M., Boletis, I. N., Dantal, J., de Fijter, J. W., Hertig, A., Neumayer, H. H., Øyen, O. M., Pascual, J., Pohanka, E., Ruiz, J. C., et al. (2009) · Clinical Transplantation · doi:10.1111/j.1399-0012.2009.01057.x · Cited by 17
A Prospective Open-Label Randomised Trial of Quinapril and/or Amlodipine in Progressive Non-Diabetic Renal Failure
MACGREGOR, M. S., Deighan, C. J., Rodger, R. S. C., & Boulton‐Jones, J. M. (2005) · Nephron Clinical Practice · doi:10.1159/000086714 · Cited by 17

Authors: Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A.
Affiliations: The Ohio State University Wexner Medical Center (US)
Louis Stokes Cleveland VA Medical Center (US)
Duke University (US)
Alexion Pharmaceuticals (United States) (US)
Corresponding author: Wilmer, William A.
Rovin, Brad H.
Hebert, Lee A.
ORCID: Rovin, Brad H.
Rao, Sunil V.
Venue: Journal of the American Society of Nephrology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2003-12
Volume: 14
Issue: 12
Pages: 3217-3232
ISSN: 1046-6673 (ISSN-L)
DOI: 10.1097/01.asn.0000100145.27188.33
OpenAlex: W2110754607
Cited by: 217
References: 168
Citations by year: 2026: 1 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 4 · 2016: 7 · 2015: 8 · 2014: 6 · 2013: 19 · 2012: 14
FWCI: 10.93
Type: journal article
Language: en
Open access: closed
Locations: Journal of the American Society of Nephrology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5u01dk039485-05)
National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK55546, P01DK055546, U10 DK 48621, U01 DK 39485)
National Center for Research Resources (M01-RR-00034, M01RR000034)
Topics: Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords: glomerular proteinuria, proteinuria reduction, chronic kidney disease, renal protection, antiproteinuric therapy, ACE inhibitors, angiotensin receptor blockers, evidence-based recommendations, pathophysiological mechanisms
MeSH terms: Humans, Kidney Diseases, Kidney Glomerulus, Monitoring, Physiologic, Proteinuria, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Glomerular Proteinuria: A Commentary

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks